Overview

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346

Status:
Not yet recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
Phase:
Phase 1
Details
Lead Sponsor:
Huazhong University of Science and Technology
Collaborator:
Innovent Biologics (Suzhou) Co. Ltd.